Corbin Capital Partners’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Corbin Capital Partners’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-928,124	Closed	-$9.37M	–	107
2022 Q4	$9.37M	Hold	928,124	–	–	2.85%	10
2022 Q3	$9.21M	Hold	928,124	–	–	2.29%	15
2022 Q2	$9.19M	Hold	928,124	–	–	2.08%	18
2022 Q1	$9.15M	Hold	928,124	–	–	1.56%	21
2021 Q4	$9.13M	Hold	928,124	–	–	1.57%	21
2021 Q3	$9.04M	Hold	928,124	–	–	1.76%	20
2021 Q2	$8.97M	Hold	928,124	–	–	1.86%	21
2021 Q1	$9.02M	Buy	+928,124	New	+$8.99M	2.13%	20

Corbin Capital Partners's BIOT Position: Q1 2023 in Review

Corbin Capital Partners sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 928,124 shares — an estimated $9.37M sold.

Corbin Capital Partners first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $9.37M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Corbin Capital Partners reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Corbin Capital Partners sold 928,124 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $9.37M.
Corbin Capital Partners first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Corbin Capital Partners's Biotech Acquisition Company Class A Ordinary Shares position peaked at $9.37M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Corbin Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.